<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495829</url>
  </required_header>
  <id_info>
    <org_study_id>ML-2020-01</org_study_id>
    <nct_id>NCT04495829</nct_id>
  </id_info>
  <brief_title>Clinical and Refractive Outcomes After Contoura® Refractive Surgery Planned Using Phorcides Surgery Planning Software</brief_title>
  <official_title>Clinical and Refractive Outcomes After Contoura® Refractive Surgery Planned Using Phorcides Surgery Planning Software</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Corneal Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science in Vision</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Corneal Consultants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the current study is to prospectively evaluate 3-month clinical outcomes&#xD;
      from LASIK performed using the Phorcides surgical planning software with Contoura&#xD;
      topography-guided ablation in both eyes of subjects with myopia and myopic astigmatism&#xD;
      seeking refractive surgery for distance correction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the current study is to prospectively evaluate 3-month clinical outcomes&#xD;
      from LASIK performed using the Phorcides surgical planning software with Contoura&#xD;
      topography-guided ablation in both eyes of subjects with myopia and myopic astigmatism&#xD;
      seeking refractive surgery for distance correction. Data will be compared to published&#xD;
      results for wavefront optimized LASIK and LASIK performed with Contoura using other&#xD;
      refractive algorithms.&#xD;
&#xD;
      The hypothesis is that use of the Phorcides planning software will result in a higher&#xD;
      percentage of eyes with residual refractive cylinder ≤ 0.25D than will be achieved with&#xD;
      wavefront-optimized (WFO) LASIK. It is also expected that unaided postoperative visual acuity&#xD;
      and visual symptoms will be improved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Residual refractive cylinder</measure>
    <time_frame>3 months postop</time_frame>
    <description>Residual refractive cylinder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected distance visual acuity</measure>
    <time_frame>3 months postop</time_frame>
    <description>Uncorrected visual acuity at distance (4-6m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual refractive sphere</measure>
    <time_frame>3 months postop</time_frame>
    <description>Residual refractive sphere</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal aberrations</measure>
    <time_frame>3 months postop</time_frame>
    <description>Measured higher order aberrations of the cornea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular aberrations</measure>
    <time_frame>3 months postop</time_frame>
    <description>Total ocular aberrations measured at sites equipped to do so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction and vision</measure>
    <time_frame>3 months postop</time_frame>
    <description>A questionnaire related to visual quality and satisfaction after surgery</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Refractive Errors</condition>
  <arm_group>
    <arm_group_label>Phorcides</arm_group_label>
    <description>Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phorcides Analytical Engine</intervention_name>
    <description>Surgery planning using the Phorcides analytical engine.</description>
    <arm_group_label>Phorcides</arm_group_label>
    <other_name>Phorcides</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects presenting for myopic LASIK correction who are eligible for treatment with&#xD;
        topography-guided ablation in both eyes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidate for Contoura excimer laser vision correction&#xD;
&#xD;
          -  Gender: males and females.&#xD;
&#xD;
          -  Age: 20 or older&#xD;
&#xD;
          -  Willing and able to provide written informed consent for participation in the study.&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits and other study procedures.&#xD;
&#xD;
          -  Good ocular health, with no pathology that compromises visual acuity (other than&#xD;
             refractive error)&#xD;
&#xD;
          -  Corrected preoperative visual acuity of 20/20 (0.0 logMAR) or better in the eye being&#xD;
             treated&#xD;
&#xD;
          -  Meet Contoura eligibility requirements (approved range): up to -8.00 D sphere, up to&#xD;
             -3.00 D cylinder, and a spherical equivalent no greater than -9.00 D&#xD;
&#xD;
          -  Desire good vision at distance in both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Corneal pathology (e.g. opacities, epithelial basement membrane dystrophy, Fuchs'&#xD;
             dystrophy, etc.)&#xD;
&#xD;
          -  Previous corneal surgery (e.g., radial keratotomy, corneal refractive surgery or&#xD;
             corneal transplant, DSAEK, DMEK, lamellar keratoplasty)&#xD;
&#xD;
          -  Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy)&#xD;
&#xD;
          -  Desire for good uncorrected near vision in one or both eyes&#xD;
&#xD;
          -  Participation in (or current participation) any investigational drug or device trial&#xD;
             within the previous 30 days prior to the start date of this trial&#xD;
&#xD;
          -  Unsuitability for the trial, in the opinion of the investigator, for any reason&#xD;
&#xD;
          -  Pregnancy or desire to become pregnant during the trial&#xD;
&#xD;
          -  Intraoperative complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D Stulting</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woolfson Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suburban Eye Specialists</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser Defined Vision</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mann Eye Institute and Laser Centers</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stulting RD, Durrie DS, Potvin RJ, Linn SH, Krueger RR, Lobanoff MC, Moshirfar M, Motwani MV, Lindquist TP, Stonecipher KG. Topography-Guided Refractive Astigmatism Outcomes: Predictions Comparing Three Different Programming Methods. Clin Ophthalmol. 2020 Apr 24;14:1091-1100. doi: 10.2147/OPTH.S244079. eCollection 2020.</citation>
    <PMID>32425495</PMID>
  </reference>
  <results_reference>
    <citation>Lobanoff M, Stonecipher K, Tooma T, Wexler S, Potvin R. Clinical outcomes after topography-guided LASIK: comparing results based on a new topography analysis algorithm with those based on manifest refraction. J Cataract Refract Surg. 2020 Jun;46(6):814-819. doi: 10.1097/j.jcrs.0000000000000176.</citation>
    <PMID>32176160</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

